Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
This transaction is the third acquisition by three different Japanese players in this segment
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Collaboration streamlines patient access to oncology clinical trials
The deal includes upfront payments, milestone payments and ongoing royalties
Subscribe To Our Newsletter & Stay Updated